Sarcomas | Specialty

The OncLive Sarcomas/TGCT condition center page is a comprehensive resource for clinical news and expert insights on tenosynovial giant cell tumor (TGCT), soft tissue sarcoma, gastrointestinal stromal tumor, Ewing sarcoma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in sarcomas and TGCT.

Dr. Schwartz on the Updated Design of the Alliance A091401 Trial in Metastatic Sarcomas

July 31st 2020

Gary K. Schwartz, MD, discusses the updated design of the phase 2 Alliance A091401 trial for metastatic sarcomas.

Dr. Schwartz on Future Research in Sarcoma

July 30th 2020

Gary K. Schwartz, MD, discusses future research in sarcoma.

Dr. Roland on the Rationale for a Neoadjuvant Checkpoint Blockade in Sarcoma

July 30th 2020

Christina L. Roland, MD, PhD, discusses the rationale for a phase 2 study evaluating neoadjuvant checkpoint blockade study in patients with undifferentiated pleomorphic sarcoma and dedifferentiated liposarcoma.

Randall Shares How Postoperative Radiotherapy Retains a Role in Soft Tissue Sarcoma

July 29th 2020

R. Lor Randall, MD, FACS, discusses preoperative radiotherapy and how it has become a standard of care for patients with soft tissue sarcoma of the extremities; however, postoperative radiation still plays a role in the paradigm, especially when wound risks are considered to be precarious.

Dr. Roland on Neoadjuvant Checkpoint Blockade in Sarcoma Subtypes

July 28th 2020

Christina L. Roland, MD, PhD, discusses the design of a randomized, phase 2 trial with nivolumab and ipilimumab in resectable retroperitoneal dedifferentiated liposarcoma, as well as radiation therapy in extremity/truncal undifferentiated pleomorphic sarcoma.

Nivolumab/Ipilimumab Shows Intriguing Clinical Activity in Metastatic Sarcomas

July 28th 2020

Gary K. Schwartz, MD, discusses the clinical findings with the combination of nivolumab and ipilimumab in patients with dedifferentiated liposarcoma and undifferentiated pleomorphic sarcoma.

European Medicines Agency Grants PRIME Access to ADP-A2M4 for Synovial Sarcoma

July 27th 2020

The European Medicines Agency has granted access to the PRIME initiative for the Specific Peptide Enhanced Affinity Receptor T-cell therapy ADP-A2M4 for the treatment of patients with synovial sarcoma.

Dr. Gronchi on the Rationale for the TRASTS Study in Soft Tissue Sarcoma

July 23rd 2020

Alessandro Gronchi, MD, discusses the rationale for the phase 2 TRASTS study in soft tissue sarcoma.

Ripretinib Takes Step Toward Chinese Approval for Advanced GIST

July 21st 2020

The China National Medical Products Administration has accepted a new drug application for ripretinib as a treatment for adult patients with advanced gastrointestinal stromal tumor who have received previous treatment with 3 or more kinase inhibitors, including imatinib.

NCCN Publishes Guidelines Listing Pexidartinib as Category 1 Recommended Therapy in TGCT

July 20th 2020

The National Comprehensive Cancer Network recently published updated Clinical Practice Guidelines in Oncology for Soft Tissue Sarcoma, listing pexidartinib as a systemic treatment for patients with tenosynovial giant cell tumor.

Dr. Schwartz on ​the Results of the Alliance A091401 Study in Metastatic Sarcoma

July 1st 2020

Gary K. Schwartz, MD, discusses results of the Alliance A091401 trial (NCT02500797) in patients with metastatic sarcoma.

Randall Issues Call for Multidisciplinary Management in Giant Cell Tumor of Bone

June 30th 2020

R. Lor Randall, MD, FACS, discusses the need for multidisciplinary collaboration in GCTB, challenges faced in the space, and directions for future research efforts.

European Panel Recommends Against Pexidartinib for Tenosynovial Giant Cell Tumor

June 27th 2020

The European Medicines Agency’s advisory group, the Committee for Medicinal Products for Human Use, has recommended against the acceptance of the marketing authorization for pexidartinib (Turalio) for the treatment of patients with tenosynovial giant cell tumor.

Dr. Tseng on Role of Neoadjuvant Systemic Therapy in High-Risk Retroperitoneal Sarcoma

June 23rd 2020

William W. Tseng, MD, discusses the potential role of neoadjuvant systemic therapy in high-risk retroperitoneal sarcoma.

LTD Changes Correlate With OS in Localized High-Risk Soft Tissue Sarcoma

June 19th 2020

A percentage change in longest tumor diameter of patients with localized high-risk soft tissue sarcoma who were treated with neoadjuvant chemotherapy was found to correlate with overall survival.

Expert Elucidates the Role of Neoadjuvant Systemic Therapy in High-Risk Retroperitoneal Sarcoma

June 19th 2020

Neoadjuvant systemic therapy was found to show a modest benefit in patients with retroperitoneal sarcoma, and the tumor response could be used as an indicator of disease biology to predict survival outcomes after surgery.

Dr. Van Tine on Next Steps With ADP-A2M4 in Advanced Solid Tumors

May 31st 2020

Brian A. Van Tine, MD, PhD, discusses next steps with ADP-A2M4 SPEAR T cells in advanced solid tumors.

Orthopedic Oncologists Recommended for Consult on Bone Sarcoma Treatment After Osteointegration

May 26th 2020

R. Lor Randall, MD, FACS, discusses the cautions medical oncologists should take for their patients with bone sarcomas who undergo limb preservation with osteointegration, and the importance of keeping orthopedic oncologists in the loop.

Case Study Shows Potential for CDK4/6 Inhibition in Metastatic Osteosarcoma

May 15th 2020

The combination of gemcitabine and ribociclib led to a radiographic and histologic response in a woman with chemotherapy-resistant metastatic CDK6-amplified osteosarcoma

FDA Approves Pomalidomide for Kaposi Sarcoma

May 15th 2020

The FDA has approved pomalidomide for patients with AIDS-related Kaposi sarcoma whose disease has become resistant to highly active antiretroviral therapy, or in patients with Kaposi sarcoma who are HIV-negative.

NEXT PAGE
PREVIOUS PAGE